Space pharmaceutical industry hopes to be future of medicine
(NewsNation) — For scientists, space could be the new frontier of medicine, particularly when it comes to creating new pharmaceuticals.
California-based Varda Space Industries is one company hoping outer space can be used to create new medications for people on Earth.
Co-founder Will Bruey told NewsNation the industry is looking beyond Earth for opportunities to 'manipulate chemistry' in new ways.
Strange flying objects reported near Arizona Air Force ranges: FAA
'The reason we make pharmaceuticals in orbit is because the lack of gravity allows us to make drug formulations that you otherwise couldn't on Earth because of Earth's gravity,' he said. 'So it's a whole new way to manipulate chemistry.'
The conditions in orbit cannot be replicated on our planet, so scientists on the ground develop pharmaceutical predictions and test them by sending modules to space. The drugs are analyzed once the capsule returns.
'They can take a formulation that used to be an IV bag and turn it into a shot, or a pill to an inhalable,' Bruey said. 'Those are what I mean by different formulations, and you can create those in the microgravity of space and then bring it back for use for people on Earth.'
New Orleans man takes 2 million steps in 30 days
The growing space industry is allowing for more research, although at the moment, it comes with a significant price tag.
Bruey hopes that, with progress, space will become just another laboratory.
'In the next few years, it will be just scaling up, so more flights, until we get to a daily cadence so that we simply look like another piece of lab equipment for the pharmaceutical industry,' he said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
25 minutes ago
- Bloomberg
Musk-Trump Feud Distracts Tesla Traders Ahead of Robotaxi Launch
After years of anticipation and broken promises, Tesla Inc. said its robotaxi service is tentatively set to roll out later this month. Options traders aren't ready to buy the hype yet. Traders had braced for the milestone to come on June 12 — before Chief Executive Officer Elon Musk said late Tuesday the company is aiming for a June 22 launch date — and their positioning in the stock's options signaled that few expected any fireworks. Options traders priced in a 5.4% move in the stock for the week ending June 13, according to data compiled by Tom Keen, options strategist at Piper Sandler. That's 24% below the stock's average realized weekly move over the past 12 months.
Yahoo
40 minutes ago
- Yahoo
Uncrustables Are on a Seemingly Unstoppable Run to $1 Billion in Sales
Sales of the Uncrustables sandwich continued to grow, despite soft peanut butter and jam sales in the most recent quarter, The J.M. Smucker Co. said. The company is poised to achieve its goal of hitting more than $1 billion in Uncrustables sales in the current fiscal year, executives said. J.M. Smucker aims to keep the momentum going with limited editions of a product known to be eaten by musicians and athletes such as Travis haven't lost their edge. Despite the fact that making making peanut butter and jelly sandwiches isn't particularly hard, Americans continue to opt for the shortcut offered by The J.M. Smucker Co. (SJM). Sales of Jif peanut butter and Smucker's jam fell year-over-year in the last quarter, while sales of the Uncrustables sandwich rose, CEO Mark Smucker said on a conference call Tuesday. Uncrustables sales leaped 15% year-over-year in fiscal year 2025, hitting $920 million, according to company executives. The sandwich now accounts for more than a tenth of annual sales at J.M. Smucker, which also sells pet food along with Folgers and Café Bustelo coffee. Hitting $1 billion in annual sales of the sandwich has been part of the company's agenda since at least 2021, when Uncrustables sales were about half that amount. Now, the mark is within striking distance. The company wants to continue building momentum with new riffs on the PB&J, robust marketing and broader distribution, Mark Smucker said at a conference in March. 'We definitely think there's growth beyond … $1 billion,' said Smucker, according to a transcript made available by AlphaSense. 'And we've talked about how long it took us to figure out how to make these things in a profitable and mass-produced high-quality way. And now that we're doing that, we can really fire on all cylinders and drive the growth.' Demand for Uncrustables has been so strong that J.M. Smucker opened a $1.1 billion plant in Alabama last year to ramp up production. And appetite for the sandwiches is expected to withstand price increases, executives said: J.M. Smucker recently raised its list price for Uncrustables for the first time in three years, Smucker said on the earnings call. (The company's 2026 forecast is based on a low-single-digit percent price bump, CFO Tucker Marshall said.) The product has long benefited from high-profile fans—from musicians like Drake to sports icons, such as Travis Kelce, according to news reports. Athletes say the snack has enough calories and protein to fuel their performance. Affinity for the sandwich has spread beyond sports fields and school cafeterias to corporate break rooms, according to a 2023 Wall Street Journal article. The Ohio-based company hopes to generate still more hype with Uncrustables fillings that are available for a limited time, Mark Smucker said on the earnings call. We have 'begun launching a regular cadence of limited edition flavors starting this summer with a new peanut butter and mixer berry spread variety,' he said. J.M. Smucker shares fell nearly 16% Tuesday after it missed fourth-quarter sales estimates and released an outlook that was more cautious than analysts expected. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
India's granaries overflow as rice stocks hit record, wheat surges
By Rajendra Jadhav MUMBAI (Reuters) -India's rice stocks in government warehouses rose 18% from a year ago to a record high for the start of June, while wheat stocks have hit their highest level in four years on higher procurement from farmers, official data showed on Wednesday. Record rice stocks will help the world's biggest exporter increase shipments, while an improvement in wheat inventories will help the federal government tame any price spikes later this year by increasing open market sales. State reserves of rice, including unmilled paddy, totalled a record 59.5 million metric tons as of June 1, far exceeding the government's target of 13.5 million tons for July 1. Wheat stocks stood at 36.9 million tons on June 1, well above the government's target of 27.6 million tons, the data showed. "Rice stocks have piled up way too much. The government really needs to bring them down before the next buying season kicks off in October," said a New Delhi-based dealer at a global trading firm. India, which accounts for around 40% of global rice exports, removed the last of its export curbs on the grain in March 2025, with the initial restrictions having been imposed in 2022. Wheat stocks have risen to a comfortable position mainly because of higher procurement, which will help New Delhi sell more wheat to bulk consumers during the lean supply season, said a Mumbai-based dealer. The government has so far brought 30 million tons of wheat from farmers, the most in four years, according to data compiled by Food Corporation of India (FCI). Disappointing harvests in the past three years and lower purchases by the FCI had pushed up prices of the staple grain and raised expectations that India may be forced to import wheat for the first time in seven years. But the buildup in stocks this year means the country should be able to meet domestic demand without imports.
